What Is vinpocetine and what are the effects of this supplement for cognitive enhancement?
Vinpocetine is a biosynthetic supplement derived from alkaloid found in the Periwinkle plant called Vinca minor.
This is a plant that grows in southern and central Europe and has been used in various cultures throughout history for numerous natural remedies.
There are over 50 alkaloids in this plant, but Vinpocetine is considered to be the most significant with well-noted benefits for memory and cognitive function.
You can buy Vinpocetine 5mg supplements on their own, but you will also find it in the best-selling nootropic stack Alpha Brain from Onnit Labs. What makes Vinpocetine so effective at boosting mental performance and brainpower?



- Increases blood flow & brain metabolism
- Supports energy, focus & memory
- Combats free radicals & oxidative damage
Vinpocetine 5mg Benefits:
Related Topics
Research studies have demonstrated that this supplement is effective at improving cognitive function across several different dynamincs.
Vinpocetine is considered to be a cerebral vasodilator. This means that it improves and increases blood flow to the brain.
The most interesting thing about this effect is that it is specific to the brain; blood pressure in other parts of the body are not affected at all.
It even targets damaged brain cells that have poor blood flow and increases circulation to these areas. This also helps to improve the amount of oxygen and glucose uptake occurring in the brain.
In following with this, Vinpocetine serves to increase the production of ATP in your cells. ATP is the main energy currency used within your neurons and other bodily cells. All of the energy you consume from foods – whether in the form of sugars (glucose) or fat (lipids) – ultimately is converted into ATP to power the fundamental operations of your cell organelles.
By raising ATP production in the brain, Vinpocetine can augment your intellectual capacity, make you feel more energized and even improve your mood. Vinpocetine also helps to transport nutrients and energy through the brain. This ensures that the neurons are able to communicate with one another effectively.
Vinpocetine is also recorded to increase the levels of many of the most important neurochemichals in your brain called neurotransmitters. These effects are recorded for the Acetylcholine, Noradrenaline, Serotonin, and Dopamine neurotransmitters.
This ultimately means that Vinpocetine leads to an increase in memory, learning capacity, speed of recall, enhanced attention span, focus, and concentration.
Additionally, your emotional mentality is improved, levels of stress and anxiety are reduced, and motivation may be increased. There is even evidence to suggest that the supplement protects neurons from toxins and keeps nerves healthy and functioning properly.
Vinpocetine Mechanism of Action:
Although the exact methods of action for Vinpocetine are not completely understood, we do have a very good general idea of the pathways it is able to influence.
The first step in all of these processes is for the supplement to be absorbed through the intestines into the bloodstream. At this point, it is able to cross over the blood-brain barrier and enter into the central nervous system. It is here that Vinpocetine goes to work, opening up blood vessels and passageways.
This is primarily responsible for enhancing the overall cerebral blood flow and circulation to the brain. As mentioned above, this is done without increasing blood pressure in any other area which means there is no risk to cardiovascular health.
This makes Vinpocetine quite distinct from stimulants like Ephedrine or Adderall which cannot specifically target the brain as vasodilators.
Overall brain metabolism is also improved due to the increased availability of glucose – the primary energy source for the brain. With better metabolism, Vinpocetine is able to positively affect the ATP production in your cells. The result is a feeling of mental clarity and the alleviation of brain fog and fatigue.
Vinpocetine also increases stimulation of the Acetylcholine, Noradrenaline, Serotonin, and Dopamine receptors in your brain.
Vinpocetine Safety:
As an herbal-derived nootropic, Vinpocetine is actually one of the safest supplements you can take. The only commonly reported side effect is being a little too energized or ‘revved-up.’ Even this normally only occurs when someone takes much more than is typically recommended.
To provide a point of comparison, Vinpocetine is actually much safer than a cup of coffee, at least when comparing the median lethal dose. Caffeine is more than twice as toxic to the human body as Vinpocetine.
The side effects of Vinpocetine may sometimes feel like you have just drunk a weak cup of coffee, but for the most part negative symptoms are not experienced.
Vinpocetine Dosage:
Typical doses of Vinpocetine range from 5 to 20 mg per day. In every capsule of Alpha Brain, you will find 5 mg of Vinpocetine and this is typically enough for most people to achieve their desired effects.
The best way to take Vinpocetine powder or tablets is with a meal and in smaller administrations two or three times a day, perhaps with breakfast and lunch or dinner. You may want to combine Vinpocetine with another nootropic like Theanine or Sulbutiamine to intensify the benefits while preventing any possible side effects related to nervousness or restlessness.
- Nivison-Smith L, O'Brien BJ, Truong M, Guo CX, Kalloniatis M, Acosta ML. Vinpocetine modulates metabolic activity and function during retinal ischemia. Am J Physiol Cell Physiol. 2015
- Ruiz-Miyazawa KW, Pinho-Ribeiro FA, Zarpelon AC, Staurengo-Ferrari L, Silva RL, Alves-Filho JC, Cunha TM, Cunha FQ, Casagrande R, Verri WA Jr. Vinpocetine reduces lipopolysaccharide-induced inflammatory pain and neutrophil recruitment in mice by targeting oxidative stress, cytokines and NF-κB. Chem Biol Interact. 2015
- Liu RT, Wang A, To E, Gao J, Cao S, Cui JZ, Matsubara JA. Vinpocetine inhibits amyloid-beta induced activation of NF-κB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells. Exp Eye Res. 2014
- Nivison-Smith L, Acosta ML, Misra S, O'Brien BJ, Kalloniatis M. Vinpocetine regulates cation channel permeability of inner retinal neurons in the ischaemic retina. Neurochem Int. 2014
- Sharma S, Deshmukh R. Vinpocetine attenuates MPTP-induced motor deficit and biochemical abnormalities in Wistar rats. Neuroscience. 2015
- Ruiz-Miyazawa KW, Zarpelon AC, Pinho-Ribeiro FA, Pavão-de-Souza GF, Casagrande R, Verri WA Jr. Vinpocetine reduces carrageenan-induced inflammatory hyperalgesia in mice by inhibiting oxidative stress, cytokine production and NF-κB activation in the paw and spinal cord. PLoS One. 2015
- Wang K, Wen L, Peng W, Li H, Zhuang J, Lu Y, Liu B, Li X, Li W, Xu Y. Vinpocetine attenuates neointimal hyperplasia in diabetic rat carotid arteries after balloon injury. PLoS One. 2014
- Wang H, Zhang K, Zhao L, Tang J, Gao L, Wei Z. Anti-inflammatory effects of vinpocetine on the functional expression of nuclear factor-kappa B and tumor necrosis factor-alpha in a rat model of cerebral ischemia-reperfusion injury. Neurosci Lett. 2014
- Ogunrin A. Effect of vinpocetine (cognitolâ„¢) on cognitive performances of a nigerian population. Ann Med Health Sci Res. 2014
- Gómez CD, Buijs RM, Sitges M. The anti-seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL-1β and TNF-α expression in rat hippocampus. J Neurochem. 2014
- Lee JY, Komatsu K, Lee BC, Miyata M, O'Neill Bohn A, Xu H, Yan C, Li JD. Vinpocetine Inhibits Streptococcus pneumoniae-Induced Upregulation of Mucin MUC5AC Expression via Induction of MKP-1 Phosphatase in the Pathogenesis of Otitis Media. J Immunol. 2015
- Zaki HF, Abdelsalam RM. Vinpocetine protects liver against ischemia-reperfusion injury. Can J Physiol Pharmacol. 2013
- Jovanović ZB, Pavlović AM, Pekmezović T, Mijajlović M, Covicković NS. Transcranial Doppler assessment of cerebral vasomotor reactivity in evaluating the effects of vinpocetine in cerebral small vessel disease: a pilot study. Ideggyogy Sz. 2013
- Xiao-Xiao T, Sen-Min W, Ding-Sheng L. Effects of vinpocetine on random skin flap survival in rats. J Reconstr Microsurg. 2013
- Jincai W, Tingfang D, Yongheng Z, Zhongmin L, Kaihua Z, Xiaohong L. Effects of vinpocetine and ozagrel on behavioral recovery of rats after global brain ischemia. J Clin Neurosci. 2014
- Zhuang J, Peng W, Li H, Lu Y, Wang K, Fan F, Li S, Xu Y. Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-κB dependent mechanisms in apoE-/- mice. PLoS One. 2013
- Herrera-Mundo N, Sitges M. Vinpocetine and α-tocopherol prevent the increase in DA and oxidative stress induced by 3-NPA in striatum isolated nerve endings. J Neurochem. 2013
- Gupta S, Singh P, Sharma BM, Sharma B. Neuroprotective effects of agomelatine and vinpocetine against chronic cerebral hypoperfusion induced vascular dementia. Curr Neurovasc Res. 2015
- Cai Y, Knight WE, Guo S, Li JD, Knight PA, Yan C. Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration. J Pharmacol Exp Ther. 2012
- Huang EW, Xue SJ, Zhang Z, Zhou JG, Guan YY, Tang YB. Vinpocetine inhibits breast cancer cells growth in vitro and in vivo. Apoptosis. 2012
- Zhang L, Yang L. Anti-inflammatory effects of vinpocetine in atherosclerosis and ischemic stroke: a review of the literature. Molecules. 2014
- Moghaddam AA, Aqil M, Ahmad FJ, Ali MM, Sultana Y, Ali A. Nanoethosomes mediated transdermal delivery of vinpocetine for management of Alzheimer's disease. Drug Deliv. 2014
- Torres KJ, Göttle P, Kremer D, Rivera JF, Aguirre-Cruz L, Corona T, Hartung HP, Küry P. Vinpocetine inhibits oligodendroglial precursor cell differentiation. Cell Physiol Biochem. 2012
- Zaitone SA, Abo-Elmatty DM, Elshazly SM. Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats. Indian J Pharmacol. 2012
- Alkuraishy HM, Al-Gareeb AI, Albuhadilly AK. Vinpocetine and pyritinol: a new model for blood rheological modulation in cerebrovascular disordersâ€"a randomized controlled clinical study. Biomed Res Int. 2014
- Nunes F, Ferreira-Rosa K, Pereira Mdos S, Kubrusly RC, Manhães AC, Abreu-Villaça Y, Filgueiras CC. Acute administration of vinpocetine, a phosphodiesterase type 1 inhibitor, ameliorates hyperactivity in a mice model of fetal alcohol spectrum disorder. Drug Alcohol Depend. 2011
- Zhao YY, Yu JZ, Li QY, Ma CG, Lu CZ, Xiao BG. TSPO-specific ligand vinpocetine exerts a neuroprotective effect by suppressing microglial inflammation. Neuron Glia Biol. 2011
- Solanki P, Prasad D, Muthuraju S, Sharma AK, Singh SB, Ilavzhagan G. Preventive effect of piracetam and vinpocetine on hypoxia-reoxygenation induced injury in primary hippocampal culture. Food Chem Toxicol. 2011
- Sitges M, Sanchez-Tafolla BM, Chiu LM, Aldana BI, Guarneros A. Vinpocetine inhibits glutamate release induced by the convulsive agent 4-aminopyridine more potently than several antiepileptic drugs. Epilepsy Res. 2011
- Abdel-Salam OM, Khadrawy YA, Salem NA, Sleem AA. Oxidative stress in a model of toxic demyelination in rat brain: the effect of piracetam and vinpocetine. Neurochem Res. 2011
- Patyar S, Prakash A, Modi M, Medhi B. Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep. 2011
- Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, Abe J, Berk BC, Li JD, Yan C. Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci U S A. 2010
- Csillik B, Mihály A, Knyihár-Csillik E. Antinociceptive effect of vinpocetine--a comprehensive survey. Ideggyogy Sz. 2010
- VishnevskiÄ AA, Korotkevich IG, Zhaparalieva ChO. [Membrane and functional effects of vinpocetine and tocopherol in rats with experimental cerebral ischemia]. Biomed Khim. 2009
- Nyakas C, Felszeghy K, Szabó R, Keijser JN, Luiten PG, Szombathelyi Z, Tihanyi K. Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model. CNS Neurosci Ther. 2009
- Medina AE. Vinpocetine as a potent antiinflammatory agent. Proc Natl Acad Sci U S A. 2010
- Tárnok K, Kiss E, Luiten PG, Nyakas C, Tihanyi K, Schlett K, Eisel UL. Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochem Int. 2008
- Valikovics A, Csányi A, Németh L. [Study of the effects of vinpocetin on cognitive functions]. Ideggyogy Sz. 2012
- Valikovics A. [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007
- Abdel Salam OM. Vinpocetine and piracetam exert antinociceptive effect in visceral pain model in mice. Pharmacol Rep. 2006
- Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003
- Gulyás B, Halldin C, Karlsson P, Chou YH, Swahn CG, Bönöczk P, Farde L. [Cerebral uptake and metabolism of (11C) Vinpocetine in monkeys: PET studies]. Orv Hetil. 1999
- Nosálová V, Machová J, Babulová A. Protective action of vinpocetine against experimentally induced gastric damage in rats. Arzneimittelforschung. 1993
- Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991
- Abdel Salam OM, Oraby FH, Hassan NS. Vinpocetine ameliorates acute hepatic damage caused by administration of carbon tetrachloride in rats. Acta Biol Hung. 2007
- Sitges M, Galván E, Nekrassov V. Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem Int. 2005
- Zhou X, Dong XW, Crona J, Maguire M, Priestley T. Vinpocetine is a potent blocker of rat NaV1.8 tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther. 2003
- Gulyás B, Halldin C, Sandell J, Karlsson P, Sóvágó J, Kárpáti E, Kiss B, Vas A, Cselényi Z, Farde L. PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects. Acta Neurol Scand. 2002
- Trejo F, Nekrassov V, Sitges M. Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings. Brain Res. 2001
- Solntseva EI, Bukanova JV, Skrebitsky VG. The nootropic drug vinpocetine modulates different types of potassium currents in molluscan neurons. Comp Biochem Physiol C Toxicol Pharmacol. 2001
- Wu SN, Li HF, Chiang HT. Vinpocetine-induced stimulation of calcium-activated potassium currents in rat pituitary GH3 cells. Biochem Pharmacol. 2001
- Pereira C, Agostinho P, Oliveira CR. Vinpocetine attenuates the metabolic dysfunction induced by amyloid beta-peptides in PC12 cells. Free Radic Res. 2000
- Bereczki D, Fekete I. A systematic review of vinpocetine therapy in acute ischaemic stroke. Eur J Clin Pharmacol. 1999
- Yao JH, Su CY, Chu XY. [Pharmacokinetics and disposition of vinpocetine in rats]. Yao Xue Xue Bao. 1994
- Hagiwara M, Endo T, Hidaka H. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem Pharmacol. 1984
- Szilágyi G, Nagy Z, Balkay L, Boros I, Emri M, Lehel S, Márián T, Molnár T, Szakáll S, Trón L, Bereczki D, Csiba L, Fekete I, Kerényi L, Galuska L, Varga J, Bönöczk P, Vas A, Gulyás B. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci. 2005
- Solntseva EI, Bukanova YuV. Cyclic GTP imitates the potentiating effect of the nootrope vinpocetine on the high-threshold A-current in mollusk neurons. Neurosci Behav Physiol. 1999
- Hitzenberger G, Schmid R, Braun W, Grandt R. Vinpocetine therapy does not change imipramine pharmacokinetics in man. Int J Clin Pharmacol Ther Toxicol. 1990
- Imamoto T, Tanabe M, Shimamoto N, Kawazoe K, Hirata M. Cerebral circulatory and cardiac effects of vinpocetine and its metabolite, apovincaminic acid, in anesthetized dogs. Arzneimittelforschung. 1984
- Feher G, Koltai K, Kesmarky G, Horvath B, Toth K, Komoly S, Szapary L. Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine. 2009
- Kemény V, Molnár S, Andrejkovics M, Makai A, Csiba L. Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients. J Clin Pharmacol. 2005
- Hadjiev D. Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogy Sz. 2003
- Dézsi L, Kis-Varga I, Nagy J, Komlódi Z, Kárpáti E. [Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke]. Acta Pharm Hung. 2002
- Gulyás B, Halldin C, Sóvágó J, Sandell J, Cselényi Z, Vas A, Kiss B, Kárpáti E, Farde L. Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine. Eur J Nucl Med Mol Imaging. 2002
- Sitges M, Nekrassov V. Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel activation. Neurochem Res. 1999
- Tretter L, Adam-Vizi V. The neuroprotective drug vinpocetine prevents veratridine-induced [Na+]i and [Ca2+]i rise in synaptosomes. Neuroreport. 1998
- Kiss B, Kárpáti E. [Mechanism of action of vinpocetine]. Acta Pharm Hung. 1996
- Feigin VL, Doronin BM, Popova TF, Gribatcheva EV, Tchervov DV. Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur J Neurol. 2001
- Rischke R, Krieglstein J. Protective effect of vinpocetine against brain damage caused by ischemia. Jpn J Pharmacol. 1991
- Grandt R, Beitinger H, Schaltenbrand R, Braun W. Vinpocetine pharmacokinetics in elderly subjects. Arzneimittelforschung. 1989
- Bereczki D, Fekete I. Vinpocetine for acute ischaemic stroke. Cochrane Database Syst Rev. 2008
- Zelles T, Franklin L, Koncz I, Lendvai B, Zsilla G. The nootropic drug vinpocetine inhibits veratridine-induced [Ca2+]i increase in rat hippocampal CA1 pyramidal cells. Neurochem Res. 2001
- Santos MS, Duarte AI, Moreira PI, Oliveira CR. Synaptosomal response to oxidative stress: effect of vinpocetine. Free Radic Res. 2000
- Miskolczi P, Kozma K, Polgár M, Vereczkey L. Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur J Drug Metab Pharmacokinet. 1990
- Bönöczk P, Gulyás B, Adam-Vizi V, Nemes A, Kárpáti E, Kiss B, Kapás M, Szántay C, Koncz I, Zelles T, Vas A. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull. 2000
- Lakics V, Sebestyén MG, Erdö SL. Vinpocetine is a highly potent neuroprotectant against veratridine-induced cell death in primary cultures of rat cerebral cortex. Neurosci Lett. 1995
- Shibota M, Kakihana M, Nagaoka A. [The effect of vinpocetine on brain glucose uptake in mice]. Nihon Yakurigaku Zasshi. 1982
- Pereira C, Agostinho P, Moreira PI, Duarte AI, Santos MS, Oliveira CR. [Neuroprotection strategies: effect of vinpocetine in vitro oxidative stress models]. Acta Med Port. 2003
- Nekrassov V, Sitges M. Vinpocetine protects from aminoglycoside antibiotic-induced hearing loss in guinea pig in vivo. Brain Res. 2000
- Krieglstein J, Rischke R. Vinpocetine increases the neuroprotective effect of adenosine in vitro. Eur J Pharmacol. 1991
- Kakihana M, Suno M, Shibota M, Hamajo K, Nagaoka A. [Protective effect of vinpocetine on experimental brain ischemia]. Nihon Yakurigaku Zasshi. 1982
- DeNoble VJ, Repetti SJ, Gelpke LW, Wood LM, Keim KL. Vinpocetine: nootropic effects on scopolamine-induced and hypoxia-induced retrieval deficits of a step-through passive avoidance response in rats. Pharmacol Biochem Behav. 1986
- Vaizova OE, VengerovskiÄ AI, Alifirova VM. [An effect of vinpocetine (cavinton) on endothelium function in patients with chronic cerebral ischemia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2006
- Bönöczk P, Panczel G, Nagy Z. Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. Eur J Ultrasound. 2002
- Horvath B, Marton Z, Halmosi R, Alexy T, Szapary L, Vekasi J, Biro Z, Habon T, Kesmarky G, Toth K. In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin Neuropharmacol. 2002
- Szakáll S, Boros I, Balkay L, Emri M, Fekete I, Kerényi L, Lehel S, Márián T, Molnár T, Varga J, Galuska L, Trón L, Bereczki D, Csiba L, Gulyás B. Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study. J Neuroimaging. 1998
- Molnár P, Erdö SL. Vinpocetine is as potent as phenytoin to block voltage-gated Na+ channels in rat cortical neurons. Eur J Pharmacol. 1995
- Gaál L, Molnár P. Effect of vinpocetine on noradrenergic neurons in rat locus coeruleus. Eur J Pharmacol. 1990
- Thal LJ, Salmon DP, Lasker B, Bower D, Klauber MR. The safety and lack of efficacy of vinpocetine in Alzheimer's disease. J Am Geriatr Soc. 1989
- Miskolczi P, Vereczkey L, Szalay L, Göndöc C. Effect of age on the pharmacokinetics of vinpocetine (Cavinton) and apovincaminic acid. Eur J Clin Pharmacol. 1987
- Miskolczi P, Vereczkey L, Szalay L, Göndöcs CS. Pharmacokinetics of vinpocetine and apovincaminic acid in patients with impaired renal function. Eur J Drug Metab Pharmacokinet. 1984
- Szeleczky G, Vereczkey L. Pharmacokinetic and metabolic studies of vinpocetine on dogs. II. Metabolism. Pol J Pharmacol Pharm. 1986
- Bereczki D, Fekete I. Vinpocetine for acute ischaemic stroke. Cochrane Database Syst Rev. 2000
- Pudleiner P, Vereczkey L. Study on the absorption of vinpocetine and apovincaminic acid. Eur J Drug Metab Pharmacokinet. 1993
- Hayakawa M. Effect of vinpocetine on red blood cell deformability in vivo measured by a new centrifugation method. Arzneimittelforschung. 1992
- Sauer D, Rischke R, Beck T, Rossberg C, Mennel HD, Bielenberg GW, Krieglstein J. Vinpocetine prevents ischemic cell damage in rat hippocampus. Life Sci. 1988
- Yasui M, Yano I, Ota K, Oshima A. Preventive effect of vinpocetine on calcifications: atherosclerosis in experimental rabbits. Acta Neurol Scand. 1989
- DeNoble VJ. Vinpocetine enhances retrieval of a step-through passive avoidance response in rats. Pharmacol Biochem Behav. 1987
- Rischke R, Krieglstein J. Effects of vinpocetine on local cerebral blood flow and glucose utilization seven days after forebrain ischemia in the rat. Pharmacology. 1990
- Bhatti JZ, Hindmarch I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol. 1987
- Subhan Z, Hindmarch I. Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur J Clin Pharmacol. 1985
- Hitzenberger G, Sommer W, Grandt R. Influence of vinpocetine on warfarin-induced inhibition of coagulation. Int J Clin Pharmacol Ther Toxicol. 1990
- Hayakawa M. Effect of vinpocetine on red blood cell deformability in stroke patients. Arzneimittelforschung. 1992
- Ishihara K, Katsuki H, Sugimura M, Satoh M. Idebenone and vinpocetine augment long-term potentiation in hippocampal slices in the guinea pig. Neuropharmacology. 1989
Article last updated on: March 13th, 2018 by Nootriment